1
|
Shing Y, Folkman J, Sullivan R,
Butterfield C, Murray J and Klagsbrun M: Heparin-affinity:
Purification of a tumor-derived capillary endothelial cell growth
factor. Science. 223:1296–1298. 1984. View Article : Google Scholar : PubMed/NCBI
|
2
|
Soulitzis N, Karyotis I, Delakas D and
Spandidos DA: Expression analysis of peptide growth factors VEGF,
FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic
hyperplasia. Int J Oncol. 29:305–314. 2006.PubMed/NCBI
|
3
|
Straume O and Akslen LA: Importance of
vascular phenotype by basic fibroblast growth factor and influence
of the angiogenic factors basic fibroblast growth factor/fibroblast
growth factor receptor-1 and EphA1/EphA2 on melanoma progression.
Am J Pathol. 160:1009–1019. 2002. View Article : Google Scholar : PubMed/NCBI
|
4
|
Compagni A, Wilgenbus P, Impagnatiello MA,
Cotten M and Christofori G: Fibroblast growth factors are required
for efficient tumor angiogenesis. Cancer Res. 60:7163–7169.
2000.PubMed/NCBI
|
5
|
Soufla G, Sifakis S, Baritaki S,
Zafiropoulos A, Koumantakis E and Spandidos DA: VEGF, FGF2, TGFB1
and TGFBR1 mRNA expression levels correlate with the malignant
transformation of the uterine cervix. Cancer Lett. 221:105–118.
2005. View Article : Google Scholar : PubMed/NCBI
|
6
|
Javerzat S, Auguste P and Bikfalvi A: The
role of fibroblast growth factors in vascular development. Trends
Mol Med. 8:483–489. 2002. View Article : Google Scholar : PubMed/NCBI
|
7
|
Schlessinger J, Plotnikov AN, Ibrahimi OA,
Eliseenkova AV, Yeh BK, Yayon A, Linhardt RJ and Mohammadi M:
Crystal structure of a ternary FGF-FGFR-heparin complex reveals a
dual role for heparin in FGFR binding and dimerization. Mol Cell.
6:743–750. 2000. View Article : Google Scholar : PubMed/NCBI
|
8
|
Pearson G, Robinson F, Beers Gibson T, Xu
BE, Karandikar M, Berman K and Cobb MH: Mitogen-activated protein
(MAP) kinase pathways: Regulation and physiological functions.
Endocr Rev. 22:153–183. 2001. View Article : Google Scholar : PubMed/NCBI
|
9
|
Thisse B and Thisse C: Functions and
regulations of fibroblast growth factor signaling during embryonic
development. Dev Biol. 287:390–402. 2005. View Article : Google Scholar : PubMed/NCBI
|
10
|
Tsang M and Dawid IB: Promotion and
attenuation of FGF signaling through the Ras-MAPK pathway. Sci
STKE. 2004:pe172004.PubMed/NCBI
|
11
|
Zhang H, Zhao X, Yan L and Li M: Similar
expression to FGF (Sef) reduces endometrial adenocarcinoma cells
proliferation via inhibiting fibroblast growth factor 2-mediated
MAPK/ERK signaling pathway. Gynecol Oncol. 122:669–674. 2011.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Hacohen N, Kramer S, Sutherland D, Hiromi
Y and Krasnow MA: sprouty encodes a novel antagonist of FGF
signaling that patterns apical branching of the Drosophila airways.
Cell. 92:253–263. 1998. View Article : Google Scholar : PubMed/NCBI
|
13
|
Gross I, Bassit B, Benezra M and Licht JD:
Mammalian sprouty proteins inhibit cell growth and differentiation
by preventing ras activation. J Biol Chem. 276:46460–46468. 2001.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Hanafusa H, Torii S, Yasunaga T, Matsumoto
K and Nishida E: Shp2, an SH2-containing protein-tyrosine
phosphatase, positively regulates receptor tyrosine kinase
signaling by dephosphorylating and inactivating the inhibitor
Sprouty. J Biol Chem. 279:22992–22995. 2004. View Article : Google Scholar : PubMed/NCBI
|
15
|
Sasaki A, Taketomi T, Kato R, Saeki K,
Nonami A, Sasaki M, Kuriyama M, Saito N, Shibuya M and Yoshimura A:
Mammalian SPRY4 suppresses Ras-independent ERK activation by
binding to Raf1. Nat Cell Biol. 5:427–432. 2003. View Article : Google Scholar : PubMed/NCBI
|
16
|
Yusoff P, Lao DH, Ong SH, Wong ES, Lim J,
Lo TL, Leong HF, Fong CW and Guy GR: Sprouty2 inhibits the Ras/MAP
kinase pathway by inhibiting the activation of Raf. J Biol Chem.
277:3195–3201. 2002. View Article : Google Scholar : PubMed/NCBI
|
17
|
Billottet C, Elkhatib N, Thiery JP and
Jouanneau J: Targets of fibroblast growth factor 1 (FGF-1) and
FGF-2 signaling involved in the invasive and tumourigenic behavior
of carcinoma cells. Mol Biol Cell. 15:4725–4734. 2004. View Article : Google Scholar : PubMed/NCBI
|
18
|
Zhang H, Li M, Zheng X, Sun Y, Wen Z and
Zhao X: Endometriotic stromal cells lose the ability to regulate
cell-survival signaling in endometrial epithelial cells in vitro.
Mol Hum Reprod. 15:653–663. 2009. View Article : Google Scholar : PubMed/NCBI
|
19
|
Abulafia O, Triest WE and Sherer DM:
Angiogenesis in malignancies of the female genital
tract. Gynecol Oncol. 72:220–231. 1999. View Article : Google Scholar : PubMed/NCBI
|
20
|
Macdonald SG, Crews CM, Wu L, Driller J,
Clark R, Erikson RL and McCormick F: Reconstitution of the
Raf-1-MEK-ERK signal transduction pathway in vitro. Mol Cell Biol.
13:6615–6620. 1993. View Article : Google Scholar : PubMed/NCBI
|
21
|
Ballif BA and Blenis J: Molecular
mechanisms mediating mammalian mitogen-activated protein kinase
(MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Differ.
12:397–408. 2001.PubMed/NCBI
|
22
|
Giavazzi R, Sennino B, Coltrini D,
Garofalo A, Dossi R, Ronca R, Tosatti MP and Presta M: Distinct
role of fibroblast growth factor-2 and vascular endothelial growth
factor on tumour growth and angiogenesis. Am J Pathol.
162:1913–1926. 2013. View Article : Google Scholar
|
23
|
Hori A, Sasada R, Matsutani E, Naito K,
Sakura Y, Fujita T and Kozai Y: Suppression of solid tumor growth
by immunoneutralizing monoclonal antibody against human basic
fibroblast growth factor. Cancer Res. 51:6180–6184. 1991.PubMed/NCBI
|
24
|
Darby S, Sahadevan K, Khan MM, Robson CN,
Leung HY and Gnanapragasam VJ: Loss of Sef (similar expression to
FGF) expression is associated with high grade and metastatic
prostate cancer. Oncogene. 25:4122–4127. 2006. View Article : Google Scholar : PubMed/NCBI
|
25
|
Murphy T, Darby S, Mathers ME and
Gnanapragasam VJ: Evidence for distinct alterations in the FGF axis
in prostate cancer progression to an aggressive clinical phenotype.
J Pathol. 220:452–460. 2010.PubMed/NCBI
|
26
|
Darby S, Murphy T, Thomas H, Robson CN,
Leung HY, Mathers ME and Gnanapragasam VJ: Similar expression to
FGF (Sef) inhibits fibroblast growth factor-induced tumourigenic
behaviour in prostate cancer cells and is downregulated in
aggressive clinical disease. Br J Cancer. 101:1891–1899. 2009.
View Article : Google Scholar : PubMed/NCBI
|
27
|
Zisman-Rozen S, Fink D, Ben-Izhak O, Fuchs
Y, Brodski A, Kraus MH, Bejar J and Ron D: Downregulation of Sef,
an inhibitor of receptor tyrosine kinase signaling, is common to a
variety of human carcinomas. Oncogene. 26:6093–6098. 2007.
View Article : Google Scholar : PubMed/NCBI
|
28
|
Wang J, Thompson B, Ren C, Ittmann M and
Kwabi-Addo B: Sprouty4, a suppressor of tumor cell motility, is
down regulated by DNA methylation in human prostate cancer.
Prostate. 66:613–624. 2006. View Article : Google Scholar : PubMed/NCBI
|
29
|
Kwabi-Addo B, Wang J, Erdem H, Vaid A,
Castro P, Ayala G and Ittmann M: The expression of Sprouty1, an
inhibitor of fibroblast growth factor signal transduction, is
decreased in human prostate cancer. Cancer Res. 64:4728–4735. 2004.
View Article : Google Scholar : PubMed/NCBI
|
30
|
Fritzsche S, Kenzelmann M, Hoffmann MJ,
Müller M, Engers R, Gröne HJ and Schulz WA: Concomitant
down-regulation of SPRY1 and SPRY2 in prostate carcinoma. Endocr
Relat Cancer. 13:839–849. 2006. View Article : Google Scholar : PubMed/NCBI
|
31
|
Lo TL, Yusoff P, Fong CW, McCaw BJ,
Phillips WA, Yang H, Wong ES, Leong HF, Zeng Q, Putti TC, et al:
The ras/mitogen-activated protein kinase pathway inhibitor and
likely tumor suppressor proteins, sprouty 1 and sprouty 2 are
deregulated in breast cancer. Cancer Res. 64:6127–6136. 2004.
View Article : Google Scholar : PubMed/NCBI
|
32
|
Faratian D, Sims AH, Mullen P, Kay C, Um
I, Langdon SP and Harrison DJ: Sprouty 2 is an independent
prognostic factor in breast cancer and may be useful in stratifying
patients for trastuzumab therapy. PLoS One. 6:e237722011.
View Article : Google Scholar : PubMed/NCBI
|
33
|
Fong CW, Chua MS, McKie AB, Ling SH, Mason
V, Li R, Yusoff P, Lo TL, Leung HY, So SK, et al: Sprouty 2, an
inhibitor of mitogen-activated protein kinase signaling, is
down-regulated in hepatocellular carcinoma. Cancer Res.
66:2048–2058. 2006. View Article : Google Scholar : PubMed/NCBI
|
34
|
Sirivatanauksorn Y, Sirivatanauksorn V,
Srisawat C, Khongmanee A and Tongkham C: Differential expression of
sprouty genes in hepatocellular carcinoma. J Surg Oncol.
105:273–276. 2012. View Article : Google Scholar : PubMed/NCBI
|
35
|
Sutterlüty H, Mayer CE, Setinek U, Attems
J, Ovtcharov S, Mikula M, Mikulits W, Micksche M and Berger W:
Down-regulation of Sprouty2 in non-small cell lung cancer
contributes to tumor malignancy via extracellular signal-regulated
kinase pathway-dependent and-independent mechanisms. Mol Cancer
Res. 5:509–520. 2007. View Article : Google Scholar : PubMed/NCBI
|
36
|
Qi J, Nakayama K, Gaitonde S, Krajewski S,
Eroshkin A, Bar-Sagi D, Bowtell D and Ronai Z: The ubiquitin ligase
Siah2 regulates tumorigenesis and metastasis by HIF-dependent and
-independent pathways. Proc Natl Acad Sci USA. 105:16713–16781.
2008. View Article : Google Scholar : PubMed/NCBI
|
37
|
Feng YH, Wu CL, Tsao CJ, Chang JG, Lu PJ,
Yeh KT, Uen YH, Lee JC and Shiau AL: Deregulated expression of
sprouty2 and microRNA-21 in human colon cancer: Correlation with
the clinical stage of the disease. Cancer Biol Ther. 11:111–121.
2011. View Article : Google Scholar : PubMed/NCBI
|
38
|
Lee SA, Ho C, Roy R, Kosinski C, Patil MA,
Tward AD, Fridlyand J and Chen X: Integration of genomic analysis
and in vivo transfection to identify sprouty2 as a candidate tumor
suppressor in liver cancer. Hepatology. 47:1200–1210. 2008.
View Article : Google Scholar : PubMed/NCBI
|
39
|
Velasco A, Pallares J, Santacana M, Gatius
S, Fernandez M, Domingo M, Valls J, Yeramian A, Encinas M, Dolcet
X, et al: Promoter hypermethylation and expression of sprouty 2 in
endometrial carcinoma. Hum Pathol. 42:185–193. 2011. View Article : Google Scholar : PubMed/NCBI
|